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ABSTRACT
Background & Aims: Hepatocellular carcinoma (HCC) is a common complication of 
chronic liver disease with diverse underlying aetiologies. REACH/REACH- 2 were 
global phase III studies investigating ramucirumab in advanced HCC (aHCC) follow-
ing sorafenib treatment. We performed an exploratory analysis of outcomes by liver 
disease aetiology and baseline serum viral load.
This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
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1  | BACKGROUND
Hepatocellular carcinoma (HCC) is the third leading cause of cancer- 
related death globally.1 Rates of HCC are highest in East Asia but are 
continuing to rise in India and most countries in Europe, North/South 
America and Oceania.2 HCC commonly occurs as a result of chronic 
liver disease secondary to viral hepatitis B (HBV) or C (HCV) infection, 
although it can also be caused by other factors such as heavy alco-
hol use (more common in developed countries).3 Additionally, the rise 
of obesity and associated metabolic disorders in developed countries 
have contributed to an increase of HCC associated with non- alcoholic 
fatty liver disease and non- alcoholic steatohepatitis (NASH) further 
adding to the complexity and diversity of HCC disease aetiologies.4
Survival outcomes can differ by HCC disease aetiology with no-
table differences between systemic treatments. Post- hoc data analy-
ses suggest that sorafenib, a first- generation tyrosine kinase inhibitor 
(TKI), is less beneficial in patients with HBV compared with other dis-
ease aetiologies while second- generation TKI cabozantinib appeared 
to be less beneficial in patients with HCV.5,6 Checkpoint inhibitor 
pembrolizumab works less well in patients with HCV versus other dis-
ease aetiologies,7 while patients with HBV loads >100 IU/mL were ex-
cluded from the trial, and have been consistently omitted from clinical 
trials with immune checkpoint inhibitors.7– 9 A detectable HBV or HCV 
load in patients with HCC is associated with poorer outcomes than 
in patients without detectable viral loads.10,11 Antiviral treatment has 
been shown to reduce the risk of developing HCC and clinical guide-
lines support treatment in patients with HCC and viral hepatitis.12– 15
REACH and REACH- 2 studied ramucirumab, an immunoglobulin G1 
monoclonal antibody to vascular endothelial growth factor 2, in patients 
with advanced HCC following sorafenib.16,17 REACH- 2 met its primary 
overall survival endpoint for ramucirumab versus placebo, demon-
strating increased overall survival in patients with baseline alpha feto-
protein (AFP) levels ≥400 ng/mL, consistent with outcomes from the 
pre- specified population of patients in the REACH study with baseline 
AFP ≥400 ng/mL.16,17 In both clinical trials, patients with chronic viral 
hepatitis (HBV or HCV) irrespective of viral load were eligible for enrol-
ment.16,17 In this exploratory analysis, we investigated the efficacy and 
safety of ramucirumab in patients with advanced HCC from REACH (pa-
tients with AFP ≥ 400 ng/mL) and REACH- 2 by liver disease aetiology.
Methods: Meta- analysis was conducted in patients with aHCC and alpha- fetoprotein 
(AFP) ≥400 ng/mL (N = 542) from REACH/REACH- 2 trials. Individual patient- level 
data were pooled with results reported by aetiology subgroup (hepatitis B [HBV] or 
C [HCV] and Other). Pre- treatment serum HBV DNA and HCV RNA were quanti-
fied using Roche COBAS AmpliPrep/COBAS TaqMan. Overall survival (OS) and 
progression- free survival (PFS) were evaluated using the Kaplan- Meier method and 
Cox proportional hazard model (stratified by study).
Results: Baseline characteristics were generally balanced between arms in each sub-
group (HBV: N = 225, HCV: N = 127, Other: N = 190). No significant difference in 
treatment effect by aetiology subgroup was detected (OS interaction P- value = .23). 
Median OS (ramucirumab vs placebo) in months was 7.7 versus 4.5 (HR 0.74, 95% 
CI 0.55– 0.99) for HBV, 8.2 versus 5.5 (HR 0.82, 95% CI 0.55– 1.23) for HCV and 8.5 
versus 5.4 (HR 0.56, 95% CI 0.40– 0.79) for Other. Ramucirumab showed similar over-
all safety profiles across subgroups. Worst outcomes were noted in patients with a 
detectable HBV load. Use of HBV antiviral therapy, irrespective of viral load, was 
beneficial for survival, liver function and liver- specific adverse events.
Conclusions: Ramucirumab improved survival across aetiology subgroups with a tol-
erable safety profile, supporting its use in patients with aHCC and elevated AFP.
K E Y W O R D S
hepatitis B, hepatitis C, hepatocellular carcinoma, ramucirumab
Lay summary
Hepatocellular carcinoma (HCC) is a common complication 
of chronic liver disease with diverse underlying aetiologies 
such as viral hepatitis, chronic alcohol consumption, and 
non- alcoholic steatohepatitis. In this analysis of two- phase 
III studies (REACH and REACH- 2), the effects of ramu-
cirumab in relation to liver disease aetiology for patients 
with advanced HCC are described in detail. In patients 
with previously treated advanced HCC and elevated alpha- 
fetoprotein, ramucirumab improved survival irrespective 
of liver disease aetiology.
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2  | METHODS AND MATERIAL S
REACH (NCT01140347) and REACH- 2 (NCT02435433) were both 
global, randomised, placebo- controlled, double- blind, phase 3 trials 
(Figure 1).16,17 Patients with advanced HCC, Barcelona clinic liver 
cancer (BCLC) stage C or B disease (refractory or not amenable to 
locoregional therapy), Child– Pugh class A liver disease (score <7), 
Eastern Cooperative Oncology Group Performance Status (ECOG 
PS) 0 or 1, and who were intolerant to or progressed on sorafenib 
were eligible. Patients with chronic viral hepatitis were eligible in 
both studies, irrespective of viral load. Treatment and management 
of chronic viral hepatitis was recommended but left up to the inves-
tigator’s discretion per local practice. REACH- 2 restricted enrolment 
to patients with baseline serum AFP concentrations of ≥400 ng/mL 
whereas REACH did not.16,17 Patients were randomised in REACH 
(1:1) and REACH- 2 (2:1) to receive ramucirumab (8 mg/kg, intrave-
nously) or placebo every 14 days (once every 2 weeks) until disease 
progression, unacceptable toxicity, or withdrawal of consent. Both 
studies complied with the Declaration of Helsinki, the International 
Conference on Harmonization Guidelines for Good Clinical Practice, 
and applicable local regulations. Ethics committees at all participat-
ing centers approved the protocol, and all patients provided written 
informed consent.16,17
A meta- analysis of individual patient level data from REACH (pa-
tients with AFP ≥400 ng/mL) and REACH- 2 was performed (pooled 
population). The pooling of patient- level data provided a substan-
tially larger patient population, enabling a more precise estimation 
of the treatment effect in aetiology subgroup analyses. All pooled 
analyses were done at the level of individual patient data, stratified 
by study.16 The aetiology subgroups included HBV, HCV and Other. 
For patients where more than one aetiology has been reported, the 
classification was prioritised according to the order of HBV, HCV 
and then Other; the Other category refers to all aetiologies other 
than HBV or HCV (e.g., significant alcohol use, steatohepatitis, and 
haemochromatosis), including missing aetiology.18 This classification 
strategy was used for all efficacy and safety analyses. Overall sur-
vival (OS) was defined as the time from randomisation to death from 
any cause, and progression- free survival (PFS) was defined as the 
time from randomisation to radiographic progression or death.16,17 
Survival was evaluated using the Kaplan- Meier method and Cox 
proportional hazard model, and log- rank test p- value was used to 
compare Kaplan- Meier curves. Objective response rate and disease 
control rate were assessed per Response Evaluation Criteria in Solid 
Tumors, version 1.1. The aetiology subgroup- by- treatment interac-
tion was tested using Wald test in the Cox model.
Pre- treatment serum HBV DNA was quantified using an HBV- 
specific polymerase chain reaction (PCR) (Roche COBAS AmpliPrep/
COBAS TaqMan HBV Test v2.0) by a central laboratory. HBV DNA 
>15 IU/mL was considered detectable and <15 IU/mL was consid-
ered undetectable. Outcomes were assessed by concomitant an-
tiviral therapy using combined treatment arms— ramucirumab and 
placebo. Pre- treatment serum HCV RNA was quantified using an 
HCV- specific PCR (Roche COBAS AmpliPrep/COBAS TaqMan HCV 
Test v2.0) by a central lab. HCV RNA >20 IU/mL was considered 
detectable and <20 IU/mL was considered undetectable.
Safety endpoints were graded per the National Cancer 
Institute Common Terminology Criteria for Adverse Events, ver-
sion 4.0 throughout the study and for 30 days after treatment 
F I G U R E  1   Clinical trial designs for REACH and REACH- 2. AFP, alpha- fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BSC, best 
supportive care; ECOG PS, Eastern Cooperative Oncology Group performance status; i.v., intravenous; N, number of participants; ORR, 
objective response rate; PFS, progression- free survival; Q2W, every 2 weeks. ClinicalTrials.gov identifier: REACH: NCT01140347, REACH- 2: 
NCT02435433
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discontinuation. Laboratory monitoring, including serum albumin 
and bilirubin levels, were measured within 14 days prior to randomi-
sation and before administration of study drug at each cycle (every 
14 days). The ALBI (albumin– bilirubin) linear predictor was used to 
evaluate overall liver function. Patients were categorised into the 
ALBI grades by applying cut- offs to the linear predictor: Grade 1: 
≤−2.60; Grade 2: > −2.60 and ≤ −1.39 and Grade 3: > −1.39.19
3  | RESULTS
Data from a total of 225 patients with HBV, 127 patients with HCV, 
and 190 patients with “Other” aetiologies (Alcohol, Steatohepatitis 
and Other) were analysed (Table 1 and Figure S1). Across all aetiolo-
gies, most patients were male, had an ECOG PS of 0, BCLC stage C 
disease, and discontinued sorafenib due to progressive disease with 
a median duration of prior sorafenib of approximately 3– 4 months. 
In the HBV aetiology subgroup, patients tended to be younger with 
higher rates of extrahepatic spread, had increased baseline AFP lev-
els, and were primarily from Asia. Significant alcohol use was found 
to be the primary driver of disease in the other aetiology subgroup 
with steatohepatitis (NASH, fatty liver) and haemochromatosis fol-
lowing. Baseline characteristics were generally balanced between 
treatment arms within each aetiology subgroup with some differ-
ences observed in baseline AFP levels.
Aetiology was not found to be a significant prognostic factor for 
OS in univariate cox regression analysis or in multivariate analyses 
after adjusting for other baseline prognostic factors. The multivari-
ate Cox regression analysis, adjusted by treatment arm, did identify 
several baseline factors significantly associated with OS including 
macrovascular invasion, ECOG PS, and AFP levels (Table S1).
Ramucirumab improved OS across all aetiology subgroups. 
Ramucirumab also provided consistent PFS benefit irrespective of 
aetiology (Figure 2A- C). The median OS for ramucirumab versus pla-
cebo was 7.7 vs 4.5 months [hazard ratio (HR) 0.7, 95% confidence 
interval (CI) 0.55- 0.99] for HBV, 8.2 versus 5.5 months (HR 0.8, 95% 
CI 0.55- 1.23) for HCV, and 8.5 versus 5.4 months (HR 0.6, 95% CI 
0.40- 0.79) for Other (Figure 2D- F). No significant difference was 
detected in treatment effect in OS and PFS by aetiology subgroup 
(OS/PFS interaction P- value = .23/.39). Objective response rate and 
disease control rate were greater in the ramucirumab group in all 
aetiologies (Table S2). A potential imbalance in baseline AFP con-
centrations between treatment arms could have influenced survival 
results in each aetiology subgroup (Table 1). When adjusting for 
baseline AFP concentration, survival outcomes remained improved 
in ramucirumab treated patients in each aetiology subgroup (Figure 
S2). The two main subgroups of patients in the “Other” aetiology cat-
egory, significant alcohol use and steatohepatitis, both had improved 
survival with ramucirumab consistent with that seen with HBV and 
HCV (Figure S3).
The most frequently reported treatment- emergent adverse 
event of Grade ≥3 in the ramucirumab group (Table 2) was hyper-
tension (HBV: 11 [8.9%], HCV: 8 [10.5%], Other: 21 [18.1%]). No new 
safety signals were detected and Grade ≥3 adverse events were con-
sistent with observations from both REACH and REACH- 2.
Survival and liver function were also assessed in REACH- 2 pa-
tients with viral aetiology that were tested by a central laboratory for 
the presence of serum HBV DNA or HCV RNA at baseline. Central 
laboratory PCR was not performed in the REACH study, which pre-
cluded analysis of HBV DNA or HCV RNA in that trial.
Of the 107 REACH- 2 patients with HBV aetiology, 106 had avail-
able PCR samples and were included in the combined treatment arm 
analysis (70 ramucirumab patients and 36 placebo patients). Patients 
with a detectable HBV load (N = 48) had poorer median OS com-
pared with those with an undetectable viral load (N = 58) (5.3 vs 
10.1 months, HR 1.45, 95% CI 0.93- 2.28) (Table S3 and Figure S4A). 
Survival in patients with a detectable HBV load was improved with 
the use of concomitant antiviral therapy (N = 36) compared with 
patients who did not receive antiviral therapy (N = 12; 5.8 vs 4.0 
months) (Figure 3). No survival difference by antiviral therapy usage 
was noted for patients with an undetectable HBV load (N = 39 con-
comitant antiviral vs N = 19 no concomitant antiviral) (10.2 vs 9.7 
months, HR 1.10, 95% CI 0.57- 2.12). Maximum change in size of tar-
geted lesions from baseline are shown in Figure S5 and appeared 
to be independent of viral load and antiviral therapy. Liver injury/
failure related adverse events were less frequent in patients taking 
concomitant antiviral therapy (Table S4). During treatment, mean 
ALBI scores remained stable, with a trend toward improvement in 
patients receiving antiviral therapy (Figure S6).
Survival outcomes by HCV load were also assessed. Of the 76 
REACH- 2 patients with HCV aetiology, 67 had available PCR sam-
ples. In the HCV group, no difference in OS was detected between 
patients with and without a detectable HCV viral load (Figure S4B) 
nor when higher PCR cut- off values (<50 [undetectable], 50– 800 
000 [low], and >800 000 [high] IU/mL) were examined (data not 
shown).
4  | DISCUSSION
HCC continues to be a global health burden, and has been increas-
ing in areas where populations have traditionally been considered 
low- risk for developing HCC.20 Chronic viral infection (HBV or 
HCV), heavy alcohol use, and non- alcoholic fatty liver disease/
NASH are known risk factors associated with HCC.21 Recently, 
survival outcomes for HCC have been shown to differ by disease 
aetiology with some systemic therapies, such as TKIs and check-
point inhibitors.5– 7 This exploratory analysis of the REACH (AFP 
≥400 ng/mL) and REACH- 2 studies provides significant evidence 
that ramucirumab improves survival across aetiology subgroups, 
with a tolerable safety profile, in patients with advanced HCC and 
elevated AFP.
The value of aetiology as a prognostic factor has been vari-
able in the literature, with studies showing both an association 
and lack thereof between disease aetiology and survival outcomes 
in HCC.22– 27 In the analysis presented here, aetiology was not 
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independently prognostic for OS, with a similar treatment benefit 
across disease aetiologies (OS/PFS interaction P- value = .23/.39). 
One explanation for this lack of prognostic difference between aeti-
ology subgroups could be the biomarker- selected population in our 
studies— patients with baseline AFP levels ≥400 ng/mL. It is known 
that patients with HCC and elevated AFP levels have poorer out-
comes than those with lower AFP levels 28 and the contribution of 
elevated AFP as a prognostic factor might be greater than that of 
HBV, HCV, and other aetiologies.29
Several other trials have assessed efficacy by baseline aetiology 
subgroups and the magnitude of benefit was not equivalent across 
subgroup and agents. In the CELESTIAL phase 3 trial, OS was im-
proved for cabozantinib versus placebo with baseline HBV aetiology 
(with or without HCV: HR 0.69, 95% CI 0.51– 0.94) more so than for 
patients with HCV aetiology (without HBV; HR 1.11, 95% CI 0.72– 
1.71).6 In the CheckMate 459 phase 3 trial, OS was improved in pa-
tients with a viral aetiology treated with nivolumab versus sorafenib 
(HBV: HR 0.77, 95% CI 0.56– 1.05; HCV: HR 0.71, 95% CI: 0.49– 1.01) 
an equivalent improvement was not observed in patients with a 
non- viral aetiology (HR 0.95, 95% CI 0.74– 1.22).30 In the RESORCE 
phase 3 trial, HBV aetiology was associated with improved OS (HR 
0.58, 95% CI 0.41– 0.82) for regorafenib versus placebo more so than 
HCV (HR 0.79 [95% CI: 0.49– 1.26]).31 In the IMbrave150 phase 3 
trial, OS was improved in patients with a viral aetiology treated with 
atezolizumab plus bevacizumab versus sorafenib (HBV: HR 0.51, 
95% CI 0.32– 0.81; HCV: HR 0.43, 95% CI 0.22– 0.87), with less im-
provement shown for patients with a non- viral aetiology (HR 0.91, 
95% CI: 0.52– 1.60).32 These studies were not powered for subgroup 
analyses, including aetiology. However, these results in combination 
with REACH/REACH- 2 data, suggest disease aetiology can affect 
efficacy outcomes for different systemic therapies, although this 
needs to be further explored.
Contrary to some contemporary trials, REACH/REACH- 2 did 
not restrict patient enrolment due to viral load levels. HBV load is 
TA B L E  1   Baseline demographics and disease characteristics in pooled REACH/REACH 2 patients
Hepatitis B Hepatitis C Other
n (%) except where indicated RAM N = 124 PL N = 101 RAM N = 76 PL N = 51 RAM N = 116 PL N = 74
Sex, male 101 (81.5) 89 (88.1) 56 (73.7) 41 (80.4) 89 (76.7) 59 (79.7)
Age, years, median 57 56 65 63 69 69
ECOG PS 0 69 (55.6) 46 (45.5) 42 (55.3) 33 (64.7) 62 (53.4) 39 (52.7)
Geographical region
Region 1 (Americas, Europe, Australia, Israel) 20 (16.1) 23 (22.8) 41 (53.9) 28 (54.9) 93 (80.2) 57 (77.0)
Region 2 (Asia excluding Japan) 85 (68.5) 64 (63.4) 9 (11.8) 6 (11.8) 7 (6.0) 8 (10.8)
Region 3 (Japan) 19 (15.3) 14 (13.9) 26 (34.2) 17 (33.3) 16 (13.8) 9 (12.2)
Child- Pugh Score A- 5 91 (73.4) 69 (68.3) 35 (46.1) 23 (45.1) 64 (55.2) 43 (58.1)
Barcelona Clinic Liver Cancer Stage C 106 (85.5) 93 (92.1) 66 (86.8) 43 (84.3) 99 (85.3) 61 (82.4)
Macrovascular invasion present 36 (29.0) 31 (30.7) 32 (42.1) 24 (47.1) 45 (38.8) 22 (29.7)
Extrahepatic spread present 99 (79.8) 84 (83.2) 47 (61.8) 36 (70.6) 80 (69.0) 51 (68.9)
Discontinued sorafenib due to PD 109 (87.9) 94 (93.1) 65 (85.5) 39 (76.5) 100 (86.2) 65 (87.8)
Discontinued sorafenib due to intolerance 15 (12.1) 7 (6.9) 11 (14.5) 12 (23.5) 16 (13.8) 9 (12.2)
Median duration of prior sorafenib (months) 3.33 3.61 3.61 4.57 4.63 4.14












Aetiology of liver disease† , n (%)
Hepatitis B virus 124 (100.0) 101 (100.0) 0 1 (2.0)‡  0 0
Hepatitis C virus 7 (5.6) 5 (5.0) 76 (100.0) 51 (100.0) 0 0
Significant alcohol use 6 (4.8) 4 (4.0) 12 (15.8) 11 (21.6) 53 (45.7) 28 (37.8)
Steatohepatitis (NASH, fatty liver) 1 (0.8) 0 1 (1.3) 1 (2.0) 24 (20.7) 10 (13.5)
Haemochromatosis 0 0 0 0 2 (1.7) 1 (1.4)
Other 6 (4.8) 1 (1.0) 0 2 (3.9) 37 (31.9) 27 (36.5)
ECOG PS, Eastern Cooperative Oncology Group Performance Status; IQR, interquartile range; N, number of patients in intent- to- treat population; n, 
number of subjects in the specified category; NASH, non- alcoholic steatohepatitis; PD, progressive disease; PL, placebo; RAM, ramucirumab.
†For patients with multiple aetiologies, the classification was prioritised according to the order of Hepatitis B, Hepatitis C, and Other; the Other 
category refers to all aetiologies other than Hepatitis B or Hepatitis C, including missing aetiology.
‡Interactive voice response system/IWRS data, entered by the investigator at the time of enrollment in REACH, indicated this patient had aetiology 
of HCV; however, based on data from the case report form, this patient had HBV with co- infection of HCV.
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known to be a poor prognostic factor and the strongest indepen-
dent predictor of death in HCC, suggesting a connection between 
HBV viral replication and tumour progression.33,34 Recently, the 
use of prophylactic antiviral therapies in patients with HCC have 
been shown to prevent HBV reactivation and improve outcomes 
(long- term recurrence- free and OS) after resection of HBV- related 
HCC.35 In a meta- analysis of 9 HBV- related HCC cohort studies, 
Wong et al.36 showed that anti- viral treatment after curative treat-
ment of chronic hepatitis B- related hepatocellular carcinoma was 
associated with a decreased risk of tumour recurrence and liver- 
related mortality and improved OS. These studies focused on pa-
tients with early/recurrent HCC, and the data suggest that anti- viral 
treatment may prevent reoccurrence, however, REACH/REACH- 2 
focused on patients with advanced HCC regardless of HBV/HCV 
loads. Due to low patient numbers in treatment groups, our analy-
sis investigating HBV/HCV status included patients from combined 
treatment arms. We found that those patients with detectable HBV 
loads had worse OS than those with undetectable HBV loads. We 
show that patients with detectable HBV DNA, who received con-
current antivirals, displayed survival benefits compared with those 
patients who did not receive antiviral therapy. Regarding safety, 
liver function was preserved with the addition of antiviral therapy 
and no additional safety signals were detected. Overall, these data 
provide evidence that patients with detectable HBV loads may 
benefit from antiviral therapy while receiving systemic therapy. 
Interestingly, this trend was not seen in patients infected with HCV. 
No difference in OS was detected when comparing patients with 
and without a detectable HCV load.
This exploratory analysis has several limitations related to the 
inclusion and exclusion criteria of both the REACH and REACH- 2 
studies. Consistent with guidelines for trial exclusion, patients with 
severe liver cirrhosis (Child Pugh class B or worse) were excluded.37,38 
In addition, our analysis was limited by inclusion of only patients with 
elevated AFP levels (≥400 ng/mL). Both trials enroled patients irre-
spective of HBV and/or HCV serum viral load, but only REACH- 2 was 
designed to collect and analyse serum viral load by a central labora-
tory, which led to limitations in sample size. Furthermore, serum viral 
loads were only assessed at baseline and we were therefore unable to 
monitor changes in viral load levels during study treatment or to care-
fully monitor the effectiveness of antiviral therapy. Finally, although 
the data for these exploratory analyses were from two phase 3 trials, 
they were not powered specifically for these post- hoc analyses.
5  | CONCLUSIONS
This exploratory analysis demonstrates a consistent treatment 
benefit with ramucirumab for patients with advanced HCC and 
AFP ≥400 ng/mL, regardless of aetiology. No significant prognos-
tic difference was observed among different disease aetiologies. 
Ramucirumab was well tolerated, with a similar safety profile in all 
aetiology subgroups.
Ethic s A pprova l  and Pat ient Consent
Both studies are complied with the Declaration of Helsinki, the 
International Conference on Harmonization Guidelines for Good 
F I G U R E  2   Progression- free survival (A– C) and overall survival (D– F) Kaplan- Meier curves by liver aetiology. Kaplan- Meier analysis 
for progression- free survival and overall survival shown by treatment arm [ramucirumab (Red) vs placebo (Grey)] for pooled REACH 
and REACH- 2 patient aetiologies; HBV (N = 124 vs N = 101), HCV (N = 76 vs N = 51), and Other (N = 116 vs N = 74). Abbreviations: CI, 
confidence interval; HR, hazard ratio; N, number of patients in intent- to- treat population; PL, placebo; RAM, ramucirumab. Wald test of 
treatment- by- subgroup interaction from stratified Cox model; stratified by study identification
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Clinical Practice, and applicable local regulations. Ethics committees 
approved the protocol followed at all participating centers, and all 
patients provided written informed consent.
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Hepatitis B Hepatitis C Other













Liver injury or failure 18 (14.5) 25 
(25.3)
18 (23.7) 16 
(31.4)
27 (23.3) 18 
(24.7)
Ascites† 3 (2.4) 4 (4.0) 5 (6.6) 1 (2.0) 7 (6.0) 4 (5.5)
Hepatic 
encephalopathy†
2 (1.6) 0 4 (5.3) 0 3 (2.6) 1 (1.4)
Hypertension 11 (8.9) 3 (3.0) 8 (10.5) 3 (5.9) 21 (18.1) 2 (2.7)
Bleeding or 
haemorrhage events








1 (0.8) 1 (1.0) 0 0 0 0




0 1 (1.0) 1 (1.3) 0 2 (1.7) 1 (1.4)
Gastrointestinal 
perforation events




0 2 (2.0) 0 2 (3.9) 1 (0.9) 1 (1.4)
Congestive heart 
failure
0 1 (1.0) 0 0 1 (0.9) 0
Infusion- related 
reactions
1 (0.8) 0 0 0 0 0
AESI, adverse event of special interest; N, number of patients in safety population; PL, placebo; 
RAM, ramucirumab.
Data are treatment- emergent adverse events of special interest irrespective of cause, according to 
either consolidated categories or †preferred terms.
TA B L E  2   Treatment- emergent Grade 
≥3 adverse events of special interest
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